Chemical and MaterialsMarket Research NewsNews

Global Primary Sclerosing Cholangitis Market Growth Drivers And Marketable Price Till- 2026 By Acorda Therapeutics, Inc. (US), Gilead Sciences, Inc. (US), NGM Biopharmaceuticals (US), Intercept Pharmaceuticals & Others

In this Primary Sclerosing Cholangitis market report, industry trends are formulated on macro level which helps clients and the businesses comprehend market place and possible future issues. This market research report involves a key data and information about the ABC industry, emerging trends, product usage, motivating factors for customers and competitors, restraints, brand positioning, and customer behaviour. A detailed market study and analysis of trends in consumer and supply chain dynamics cited in this report helps businesses draw the strategies about sales, marketing, advertising, and promotion. This finest Primary Sclerosing Cholangitis market research report is generated with the expertise and innovation of a team of researchers, forecasters, analysts and managers.

Ask For Complimentary Sample PDF | Request At https://databridgemarketresearch.com/request-a-sample/?dbmr=global-primary-sclerosing-cholangitis-market

This Primary Sclerosing Cholangitis market research report predicts the size of the market with information on key vendor revenues, development of the industry by upstream & downstream, industry progress, key companies, along with type segment & market application. All statistical and numerical data mentioned in the report is symbolized with the help of graphs and charts which eases the understanding of facts and figures. To succeed in this competitive age, it is very imperative to get well-versed about the major happenings in the market which is possible only with the excellent market report like this one.

Market Analysis: 

Global Primary Sclerosing Cholangitis Market is expected to rise gradually to an estimated value of USD 157.13 million by 2026, registering a CAGR of 3.7% in the forecast period of 2019-2026 with the annual sales of USD 117.5 million in the year of 2018. This rise in market value can be attributed to the increasing awareness and concerns regarding the health of patients.

Key Market Competitors: 

Few of the major competitors currently working in the primary sclerosing cholangitis market are Acorda Therapeutics, Inc. (US), Gilead Sciences, Inc. (US), NGM Biopharmaceuticals (US), Intercept Pharmaceuticals, Inc. (US), Dr. Falk Pharma GmbH (Germany), ALLERGAN (Ireland), Takeda Pharmaceutical Company Limited. (Japan), DURECT CORPORATION (US), Conatus Pharmaceuticals, Inc. (US), Sirnaomics, Inc. (US), and HighTide Therapeutics Inc. (China), Glenmark (India), Impax Laboratories, LLC (US), Mylan N.V. (US), Teva Pharmaceuticals Industries Ltd. (Israel) and few among others.

Market Drivers

Rise in incidence and prevalence rate of liver failure and bile cancer associated with PSC.

Large No. of pipeline molecules is expected to drive the growth of the market.

Market Restraints

Withdrawal of novel molecules from late stage clinical trials will restrain the growth of the market.

Organ transplantation remains the alternative which is associated with many risk factors like relapse of the disease.

Lack of skilled expertise in remote areas

Fewer Government initiatives taken in this direction.

Table of Contents

Introduction

1.Market Segmentation

2.Market Overview

3.Executive Summary

4.Premium Insights

5.Global, By Component

6.Product Type

7.Delivery

8.Industry Type

9.Geography

Get detailed toc @ https://databridgemarketresearch.com/toc/?dbmr=global-primary-sclerosing-cholangitis-market

Segmentation: 

By Type

Classic PSC

Small-duct PSC

PSC associated with autoimmune hepatitis

By Treatment Type

Ursodeoxycholic acid

Obeticholic Acid

Methotrexate

Corticosteroids

Others

By Symptom Control

Antihistamines

Cholestyramine

Antibacterials

Opioid Antagonists

Colestipol

Others

By End- User

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

By Geography

North America

US.

Canada

Mexico

South America

Brazil

Argentina

Rest of South America

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Turkey

Belgium

Netherlands

Switzerland

Rest of Europe

Asia-Pacific

Japan

China

South Korea

India

Australia

Singapore

Thailand

Malaysia

Indonesia

Philippines

Rest of Asia Pacific

Middle East & Africa

South Africa

Egypt

Saudi Arabia

United Arab Emirates

Israel

Rest of Middle East & Africa

Key Developments in the Market:

On 19th January, 2016, Acorda Therapeutics, Inc. announced that it entered into an agreement to acquire Biotie Therapies Corp. According to the agreement, the company will acquire the four pipeline products that include BTT1023, a fully human monoclonal antibody in Phase 2 development for treatment of primary sclerosing cholangitis (PSC) which will help company to grow.

On 27th March, 2019, Gilead Sciences, Inc. announced the company’s research and development programs in primary sclerosing cholangitis (PSC) will be presented at The International Liver Congress™ 2019 in Vienna. Currently the novel molecule, Cilofexor has not get the approval but once it gets approval it will generate the revenue for the company and contribute towards the growth of the market.

Competitive Analysis: 

Global primary sclerosing cholangitis market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of primary sclerosing cholangitis market for global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Inquiry For Customize Report With Discount at : https://databridgemarketresearch.com/inquire-before-buying/?dbmr=global-primary-sclerosing-cholangitis-market

Contact:

Data Bridge Market Research

Tel: +1-888-387-2818

Email: Sopan.gedam@databridgemarketresearch.com

 

 

 

 

 

Tags

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Close